MicroRNAs as Regulators, Biomarkers and Therapeutic Targets in the Drug Resistance of Colorectal Cancer

Cellular Physiology and Biochemistry

Volumn 40, Issue 1-2, 2016, Pages 62-76

  Xie, Tao ^a   Huang, Mengxi ^b   Wang, Ye ^a   Wang, Liya ^b   Chen, Cheng ^b   Chu, Xiaoyuan ^a,b  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

^b NANJING UNIVERSITY   (China)

Author keywords

Colorectal cancer; Drug resistance; MicroRNA

Indexed keywords

ABC TRANSPORTER; ENZYME; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; FLUOROURACIL; MICRORNA; OXALIPLATIN; SOMATOMEDIN C RECEPTOR; TUMOR MARKER; VASCULOTROPIN; VASCULOTROPIN RECEPTOR;

APOPTOSIS; AUTOPHAGY; CANCER RESISTANCE; COLORECTAL CANCER; DRUG TARGETING; GENE EXPRESSION; HUMAN; MOLECULAR BIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; TREATMENT RESPONSE; COLORECTAL NEOPLASMS; DRUG RESISTANCE; GENETICS; METABOLISM; MOLECULARLY TARGETED THERAPY; TREATMENT OUTCOME;

BIOMARKERS, TUMOR; COLORECTAL NEOPLASMS; DRUG RESISTANCE, NEOPLASM; HUMANS; MICRORNAS; MOLECULAR TARGETED THERAPY; TREATMENT OUTCOME;

EID: 84995790763     PISSN: 10158987     EISSN: 14219778     Source Type: Journal    
DOI: 10.1159/000452525     Document Type: Review

References (106)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D: Global cancer statistics. CA Cancer J Clin 2011;61:69-90.
2. Nishida N, Yamashita S, Mimori K, Sudo T, Tanaka F, Shibata K, Yamamoto H, Ishii H, Doki Y, Mori M: MicroRNA-10b is a prognostic indicator in colorectal cancer and confers resistance to the chemotherapeutic agent 5-fluorouracil in colorectal cancer cells. Ann Surg Oncol 2012;19:3065-3071.
3. Chai J, Dong W, Xie C, Wang L, Han DL, Wang S, Guo HL, Zhang ZL: MicroRNA-494 sensitizes colon cancer cells to fluorouracil through regulation of DPYD. IUBMB Life 2015;67:191-201.
4. Stiegelbauer V, Perakis S, Deutsch A, Ling H, Gerger A, Pichler M: MicroRNAs as novel predictive biomarkers and therapeutic targets in colorectal cancer. World J Gastroenterol 2014;20:11727-11735.
5. Valeri N, Gasparini P, Braconi C, Paone A, Lovat F, Fabbri M, Sumani KM, Alder H, Amadori D, Patel T, Nuovo GJ, Fishel R, Croce CM: MicroRNA-21 induces resistance to 5-fluorouracil by down-regulating human DNA MutS homolog 2 (hMSH2). Proc Natl Acad Sci U S A 2010;107:21098-21103.
6. Song B, Wang Y, Xi Y, Kudo K, Bruheim S, Botchkina GI, Gavin E, Wan Y, Formentini A, Kornmann M, Fodstad O, Ju J: Mechanism of chemoresistance mediated by miR-140 in human osteosarcoma and colon cancer cells. Oncogene 2009;28:4065-4074.
7. Boni V, Bitarte N, Cristobal I, Zarate R, Rodriguez J, Maiello E, Garcia-Foncillas J, Bandres E: miR-192/miR-215 influence 5-fluorouracil resistance through cell cycle-mediated mechanisms complementary to its post-transcriptional thymidilate synthase regulation. Mol Cancer Ther 2010;9:2265-2275.
8. Mekenkamp LJ, Tol J, Dijkstra JR, de Krijger I, Vink-Borger ME, van Vliet S, Teerenstra S, Kamping E, Verwiel E, Koopman M, Meijer GA, van Krieken JH, Kuiper R, Punt CJ, Nagtegaal ID: Beyond KRAS mutation status: influence of KRAS copy number status and microRNAs on clinical outcome to cetuximab in metastatic colorectal cancer patients. BMC Cancer 2012;12:292.
9. Ha M, Kim VN: Regulation of microRNA biogenesis. Nat Rev Mol Cell Biol 2014;15:509-524.
10. Xu K, Liu X, Mao X, Xue L, Wang R, Chen L, Chu X: MicroRNA-149 suppresses colorectal cancer cell migration and invasion by directly targeting forkhead box transcription factor FOXM1. Cell Physiol Biochem 2015;35:499-515.
11. Fang Y, Sun B, Xiang J, Chen Z: MiR-301a promotes colorectal cancer cell growth and invasion by directly targeting SOCS6. Cell Physiol Biochem 2015;35:227-236.
12. Li HT, Zhang H, Chen Y, Liu XF, Qian J: MiR-423-3p enhances cell growth through inhibition of p21Cip1/Waf1 in colorectal cancer. Cell Physiol Biochem 2015;37:1044-1054.
13. Zhang B, Pan X, Cobb GP, Anderson TA: microRNAs as oncogenes and tumor suppressors. Dev Biol 2007;302:1-12.
14. Rossi S, Kopetz S, Davuluri R, Hamilton SR, Calin GA: MicroRNAs, ultraconserved genes and colorectal cancers. Int J Biochem Cell Biol 2010;42:1291-1297.
15. Zheng T, Wang J, Chen X, Liu L: Role of microRNA in anticancer drug resistance. Int J Cancer 2010;126:2-10.
16. Dong Y, Wu WK, Wu CW, Sung JJ, Yu J, Ng SS: MicroRNA dysregulation in colorectal cancer: a clinical perspective. Br J Cancer 2011;104:893-898.
17. Nies AT, Magdy T, Schwab M, Zanger UM: Role of ABC transporters in fluoropyrimidine-based chemotherapy response. Adv Cancer Res 2015;125:217-243.
18. Walko CM, Lindley C: Capecitabine: a review. Clin Ther 2005;27:23-44.
19. Rabik CA, Dolan ME: Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treat Rev 2007;33:9-23.
20. Raymond E, Faivre S, Chaney S, Woynarowski J, Cvitkovic E: Cellular and molecular pharmacology of oxaliplatin. Mol Cancer Ther 2002;1:227-235.
21. Arnould S, Hennebelle I, Canal P, Bugat R, Guichard S: Cellular determinants of oxaliplatin sensitivity in colon cancer cell lines. Eur J Cancer 2003;39:112-119.
22. Rakitina TV, Vasilevskaya IA, O'Dwyer PJ: Additive interaction of oxaliplatin and 17-allylamino-17-demethoxygeldanamycin in colon cancer cell lines results from inhibition of nuclear factor kappaB signaling. Cancer Res 2003;63:8600-8605.
23. Arango D, Wilson AJ, Shi Q, Corner GA, Aranes MJ, Nicholas C, Lesser M, Mariadason JM, Augenlicht LH: Molecular mechanisms of action and prediction of response to oxaliplatin in colorectal cancer cells. Br J Cancer 2004;91:1931-1946.
24. Griffiths GJ, Koh MY, Brunton VG, Cawthorne C, Reeves NA, Greaves M, Tilby MJ, Pearson DG, Ottley CJ, Workman P, Frame MC, Dive C: Expression of kinase-defective mutants of c-Src in human metastatic colon cancer cells decreases Bcl-xL and increases oxaliplatin-and Fas-induced apoptosis. J Biol Chem 2004;279:46113-46121.
25. Normanno N, Tejpar S, Morgillo F, De Luca A, Van Cutsem E, Ciardiello F: Implications for KRAS status and EGFR-targeted therapies in metastatic CRC. Nat Rev Clin Oncol 2009;6:519-527.
26. Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, Bets D, Mueser M, Harstrick A, Verslype C, Chau I, Van Cutsem E: Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004;351:337-345.
27. Van Cutsem E, Peeters M, Siena S, Humblet Y, Hendlisz A, Neyns B, Canon JL, Van Laethem JL, Maurel J, Richardson G, Wolf M, Amado RG: Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 2007;25:1658-1664.
28. Amado RG, Wolf M, Peeters M, Van Cutsem E, Siena S, Freeman DJ, Juan T, Sikorski R, Suggs S, Radinsky R, Patterson SD, Chang DD: Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008;26:1626-1634.
29. Karapetis CS, Khambata-Ford S, Jonker DJ, O'Callaghan CJ, Tu D, Tebbutt NC, Simes RJ, Chalchal H, Shapiro JD, Robitaille S, Price TJ, Shepherd L, Au HJ, Langer C, Moore MJ, Zalcberg JR: K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 2008;359:1757-1765.
30. Di Nicolantonio F, Martini M, Molinari F, Sartore-Bianchi A, Arena S, Saletti P, De Dosso S, Mazzucchelli L, Frattini M, Siena S, Bardelli A: Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol 2008;26:5705-5712.
31. Bardelli A, Corso S, Bertotti A, Hobor S, Valtorta E, Siravegna G, Sartore-Bianchi A, Scala E, Cassingena A, Zecchin D, Apicella M, Migliardi G, Galimi F, Lauricella C, Zanon C, Perera T, Veronese S, Corti G, Amatu A, Gambacorta M, Diaz LA, Jr., Sausen M, Velculescu VE, Comoglio P, Trusolino L, Di Nicolantonio F, Giordano S, Siena S: Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer. Cancer Discov 2013;3:658-673.
32. Warren RS, Yuan H, Matli MR, Gillett NA, Ferrara N: Regulation by vascular endothelial growth factor of human colon cancer tumorigenesis in a mouse model of experimental liver metastasis. J Clin Invest 1995;95:1789-1797.
33. Zerbini G, Lorenzi M, Palini A: Tumor angiogenesis. N Engl J Med 2008;359:763; author reply 764.
34. Zhang W, Zou C, Pan L, Xu Y, Qi W, Ma G, Hou Y, Jiang P: MicroRNA-140-5p inhibits the progression of colorectal cancer by targeting VEGFA. Cell Physiol Biochem 2015;37:1123-1133.
35. Ellis LM, Hicklin DJ: VEGF-targeted therapy: mechanisms of anti-tumour activity. Nat Rev Cancer 2008;8:579-591.
36. Holash J, Davis S, Papadopoulos N, Croll SD, Ho L, Russell M, Boland P, Leidich R, Hylton D, Burova E, Ioffe E, Huang T, Radziejewski C, Bailey K, Fandl JP, Daly T, Wiegand SJ, Yancopoulos GD, Rudge JS: VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc Natl Acad Sci U S A 2002;99:11393-11398.
37. Jimenez X, Lu D, Brennan L, Persaud K, Liu M, Miao H, Witte L, Zhu Z: A recombinant, fully human, bispecific antibody neutralizes the biological activities mediated by both vascular endothelial growth factor receptors 2 and 3. Mol Cancer Ther 2005;4:427-434.
38. Grothey A, Cutsem EV, Sobrero A, Siena S, Falcone A, Ychou M, Humblet Y, Bouché O, Mineur L, Barone C, Adenis A, Tabernero J, Yoshino T, Lenz H-J, Goldberg RM, Sargent DJ, Cihon F, Cupit L, Wagner A, Laurent D: Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. The Lancet 2013;381:303-312.
39. Lenz HJ, Stintzing S, Loupakis F: TAS-102, a novel antitumor agent: a review of the mechanism of action. Cancer Treat Rev 2015;41:777-783.
40. Deng J, Lei W, Fu JC, Zhang L, Li JH, Xiong JP: Targeting miR-21 enhances the sensitivity of human colon cancer HT-29 cells to chemoradiotherapy in vitro. Biochem Biophys Res Commun 2014;443:789-795.
41. Li T, Gao F, Zhang XP: miR-203 enhances chemosensitivity to 5-fluorouracil by targeting thymidylate synthase in colorectal cancer. Oncol Rep 2015;33:607-614.
42. Li P-L, Zhang X, Wang L-L, Du L-T, Yang Y-M, Li J, Wang C-X: MicroRNA-218 is a prognostic indicator in colorectal cancer and enhances 5-fluorouracil-induced apoptosis by targeting BIRC5. Carcinogenesis 2015;36:1484-1493.
43. Offer SM, Butterfield GL, Jerde CR, Fossum CC, Wegner NJ, Diasio RB: microRNAs miR-27a and miR-27b directly regulate liver dihydropyrimidine dehydrogenase expression through two conserved binding sites. Mol Cancer Ther 2014;13:742-751.
44. Amstutz U, Froehlich TK, Largiader CR: Dihydropyrimidine dehydrogenase gene as a major predictor of severe 5-fluorouracil toxicity. Pharmacogenomics 2011;12:1321-1336.
45. Amstutz U, Offer SM, Sistonen J, Joerger M, Diasio RB, Largiader CR: Polymorphisms in MIR27A Associated with Early-Onset Toxicity in Fluoropyrimidine-Based Chemotherapy. Clin Cancer Res 2015;21:2038-2044.
46. Li X, Li X, Liao D, Wang X, Wu Z, Nie J, Bai M, Fu X, Mei Q, Han W: Elevated microRNA-23a Expression Enhances the Chemoresistance of Colorectal Cancer Cells with Microsatellite Instability to 5-Fluorouracil by Directly Targeting ABCF1. Curr Protein Pept Sci 2015;16:301-309.
47. Shang J, Yang F, Wang Y, Wang Y, Xue G, Mei Q, Wang F, Sun S: MicroRNA-23a antisense enhances 5-fluorouracil chemosensitivity through APAF-1/caspase-9 apoptotic pathway in colorectal cancer cells. J Cell Biochem 2014;115:772-784.
48. Wang CJ, Stratmann J, Zhou ZG, Sun XF: Suppression of microRNA-31 increases sensitivity to 5-FU at an early stage, and affects cell migration and invasion in HCT-116 colon cancer cells. BMC Cancer 2010;10:616.
49. Zhang Y, Hu X, Miao X, Zhu K, Cui S, Meng Q, Sun J, Wang T: MicroRNA-425-5p regulates chemoresistance in colorectal cancer cells via regulation of Programmed Cell Death 10. J Cell Mol Med 2016;20:360-369.
50. Li Q, Liang X, Wang Y, Meng X, Xu Y, Cai S, Wang Z, Liu J, Cai G: miR-139-5p Inhibits the Epithelial-Mesenchymal Transition and Enhances the Chemotherapeutic Sensitivity of Colorectal Cancer Cells by Downregulating BCL2. Sci Rep 2016;6:27157.
51. Miyazaki S, Yamamoto H, Miyoshi N, Wu X, Ogawa H, Uemura M, Nishimura J, Hata T, Takemasa I, Mizushima T, Konno M, Doki Y, Mori M, Ishii H: A Cancer Reprogramming Method Using MicroRNAs as a Novel Therapeutic Approach against Colon Cancer: Research for Reprogramming of Cancer Cells by MicroRNAs. Ann Surg Oncol 2015;22 Suppl 3:S1394-1401.
52. Arlanov R, Lang T, Jedlitschky G, Schaeffeler E, Ishikawa T, Schwab M, Nies AT: Functional characterization of common protein variants in the efflux transporter ABCC11 and identification of T546M as functionally damaging variant. Pharmacogenomics J 2016;16:193-201.
53. Guo Y, Kotova E, Chen ZS, Lee K, Hopper-Borge E, Belinsky MG, Kruh GD: MRP8, ATP-binding cassette C11 (ABCC11), is a cyclic nucleotide efflux pump and a resistance factor for fluoropyrimidines 2',3'-dideoxycytidine and 9'-(2'-phosphonylmethoxyethyl)adenine. J Biol Chem 2003;278:29509-29514.
54. To KK, Leung WW, Ng SS: Exploiting a novel miR-519c-HuR-ABCG2 regulatory pathway to overcome chemoresistance in colorectal cancer. Exp Cell Res 2015;338:222-231.
55. Hlavata I, Mohelnikova-Duchonova B, Vaclavikova R, Liska V, Pitule P, Novak P, Bruha J, Vycital O, Holubec L, Treska V, Vodicka P, Soucek P: The role of ABC transporters in progression and clinical outcome of colorectal cancer. Mutagenesis 2012;27:187-196.
56. Zhang H, Tang J, Li C, Kong J, Wang J, Wu Y, Xu E, Lai M: MiR-22 regulates 5-FU sensitivity by inhibiting autophagy and promoting apoptosis in colorectal cancer cells. Cancer Lett 2015;356:781-790.
57. Wu H, Liang Y, Shen L, Shen L: MicroRNA-204 modulates colorectal cancer cell sensitivity in response to 5-fluorouracil-based treatment by targeting high mobility group protein A2. Biol Open 2016;5:563-570.
58. Zhou Y, Wan G, Spizzo R, Ivan C, Mathur R, Hu X, Ye X, Lu J, Fan F, Xia L, Calin GA, Ellis LM, Lu X: miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase. Mol Oncol 2014;8:83-92.
59. Chai H, Liu M, Tian R, Li X, Tang H: miR-20a targets BNIP2 and contributes chemotherapeutic resistance in colorectal adenocarcinoma SW480 and SW620 cell lines. Acta Biochim Biophys Sin (Shanghai) 2011;43:217-225.
60. Zhang Y, Geng L, Talmon G, Wang J: MicroRNA-520g confers drug resistance by regulating p21 expression in colorectal cancer. J Biol Chem 2015;290:6215-6225.
61. You H, Mak TW: Crosstalk between p53 and FOXO transcription factors. Cell Cycle 2005;4:37-38.
62. Zhang L, Pickard K, Jenei V, Bullock MD, Bruce A, Mitter R, Kelly G, Paraskeva C, Strefford J, Primrose J, Thomas GJ, Packham G, Mirnezami AH: miR-153 supports colorectal cancer progression via pleiotropic effects that enhance invasion and chemotherapeutic resistance. Cancer Res 2013;73:6435-6447.
63. Tan S, Shi H, Ba M, Lin S, Tang H, Zeng X, Zhang X: miR-409-3p sensitizes colon cancer cells to oxaliplatin by inhibiting Beclin-1-mediated autophagy. Int J Mol Med 2016;37:1030-1038.
64. Qian X, Yu J, Yin Y, He J, Wang L, Li Q, Zhang LQ, Li CY, Shi ZM, Xu Q, Li W, Lai LH, Liu LZ, Jiang BH: MicroRNA-143 inhibits tumor growth and angiogenesis and sensitizes chemosensitivity to oxaliplatin in colorectal cancers. Cell Cycle 2013;12:1385-1394.
65. Zhou J, Lv L, Lin C, Hu G, Guo Y, Wu M, Tian B, Li X: Combinational treatment with microRNA133b and cetuximab has increased inhibitory effects on the growth and invasion of colorectal cancer cells by regulating EGFR. Mol Med Rep 2015;12:5407-5414.
66. Yokobori T, Yajima R, Morita H, Fujii T, Yamaguchi S, Altan B, Tsutsumi S, Asao T, Kuwano H: MicroRNA-7 expression in colorectal cancer is associated with poor prognosis and regulates cetuximab sensitivity via EGFR regulation. Carcinogenesis 2014:bgu242.
67. Mussnich P, Rosa R, Bianco R, Fusco A, D'Angelo D: MiR-199a-5p and miR-375 affect colon cancer cell sensitivity to cetuximab by targeting PHLPP1. Expert Opin Ther Targets 2015;19:1017-1026.
68. Schetter AJ, Leung SY, Sohn JJ, Zanetti KA, Bowman ED, Yanaihara N, Yuen ST, Chan TL, Kwong DL, Au GK: MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma. Jama 2008;299:425-436.
69. Carames C, Cristobal I, Moreno V, del Puerto L, Moreno I, Rodriguez M, Marin JP, Correa AV, Hernandez R, Zenzola V, Hernandez T, Leon A, Martin JI, Sanchez-Fayos P, Garcia-Olmo D, Rojo F, Goel A, Fernandez-Acenero MJ, Garcia-Foncillas J: MicroRNA-21 predicts response to preoperative chemoradiotherapy in locally advanced rectal cancer. Int J Colorectal Dis 2015;30:899-906.
70. Lopes-Ramos CM, Habr-Gama A, de Souza Quevedo B, Felício NM, Bettoni F, Koyama FC, Asprino PF, Galante PA, Gama-Rodrigues J, Camargo AA: Overexpression of miR-21-5p as a predictive marker for complete tumor regression to neoadjuvant chemoradiotherapy in rectal cancer patients. BMC medical genomics 2014;7:1.
71. Ma Y, Zhang P, Wang F, Zhang H, Yang J, Peng J, Liu W, Qin H: miR-150 as a potential biomarker associated with prognosis and therapeutic outcome in colorectal cancer. Gut 2012;61:1447-1453.
72. Takahashi M, Cuatrecasas M, Balaguer F, Hur K, Toiyama Y, Castells A, Boland CR, Goel A: The clinical significance of MiR-148a as a predictive biomarker in patients with advanced colorectal cancer. PLoS One 2012;7:e46684.
73. Perez-Carbonell L, Sinicrope FA, Alberts SR, Oberg AL, Balaguer F, Castells A, Boland CR, Goel A: MiR-320e is a novel prognostic biomarker in colorectal cancer. Br J Cancer 2015;113:83-90.
74. Della Vittoria Scarpati G, Falcetta F, Carlomagno C, Ubezio P, Marchini S, De Stefano A, Singh VK, D'Incalci M, De Placido S, Pepe S: A specific miRNA signature correlates with complete pathological response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer. Int J Radiat Oncol Biol Phys 2012;83:1113-1119.
75. Svoboda M, Sana J, Fabian P, Kocakova I, Gombosova J, Nekvindova J, Radova L, Vyzula R, Slaby O: MicroRNA expression profile associated with response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer patients. Radiat Oncol 2012;7:195.
76. Molina-Pinelo S, Carnero A, Rivera F, Estevez-Garcia P, Bozada JM, Limon ML, Benavent M, Gomez J, Pastor MD, Chaves M, Suarez R, Paz-Ares L, de la Portilla F, Carranza-Carranza A, Sevilla I, Vicioso L, Garcia-Carbonero R: MiR-107 and miR-99a-3p predict chemotherapy response in patients with advanced colorectal cancer. BMC Cancer 2014;14:656.
77. Hansen TF, Sorensen FB, Lindebjerg J, Jakobsen A: The predictive value of microRNA-126 in relation to first line treatment with capecitabine and oxaliplatin in patients with metastatic colorectal cancer. BMC Cancer 2012;12:83.
78. Boisen MK, Dehlendorff C, Linnemann D, Nielsen BS, Larsen JS, Osterlind K, Nielsen SE, Tarpgaard LS, Qvortrup C, Pfeiffer P, Hollander NH, Keldsen N, Hansen TF, Jensen BB, Hogdall EV, Jensen BV, Johansen JS: Tissue microRNAs as predictors of outcome in patients with metastatic colorectal cancer treated with first line Capecitabine and Oxaliplatin with or without Bevacizumab. PLoS One 2014;9:e109430.
79. Rasmussen MH, Jensen NF, Tarpgaard LS, Qvortrup C, Romer MU, Stenvang J, Hansen TP, Christensen LL, Lindebjerg J, Hansen F, Jensen BV, Hansen TF, Pfeiffer P, Brunner N, Orntoft TF, Andersen CL: High expression of microRNA-625-3p is associated with poor response to first-line oxaliplatin based treatment of metastatic colorectal cancer. Mol Oncol 2013;7:637-646.
80. Mosakhani N, Lahti L, Borze I, Karjalainen-Lindsberg ML, Sundstrom J, Ristamaki R, Osterlund P, Knuutila S, Sarhadi VK: MicroRNA profiling predicts survival in anti-EGFR treated chemorefractory metastatic colorectal cancer patients with wild-type KRAS and BRAF. Cancer Genet 2012;205:545-551.
81. Igarashi H, Kurihara H, Mitsuhashi K, Ito M, Okuda H, Kanno S, Naito T, Yoshii S, Takahashi H, Kusumi T, Hasegawa T, Sukawa Y, Adachi Y, Okita K, Hirata K, Imamura Y, Baba Y, Imai K, Suzuki H, Yamamoto H, Nosho K, Shinomura Y: Association of MicroRNA-31-5p with Clinical Efficacy of Anti-EGFR Therapy in Patients with Metastatic Colorectal Cancer. Ann Surg Oncol 2015;22:2640-2648.
82. Pichler M, Winter E, Ress AL, Bauernhofer T, Gerger A, Kiesslich T, Lax S, Samonigg H, Hoefler G: miR-181a is associated with poor clinical outcome in patients with colorectal cancer treated with EGFR inhibitor. J Clin Pathol 2014;67:198-203.
83. Cappuzzo F, Sacconi A, Landi L, Ludovini V, Biagioni F, D'Incecco A, Capodanno A, Salvini J, Corgna E, Cupini S, Barbara C, Fontanini G, Crino L, Blandino G: MicroRNA signature in metastatic colorectal cancer patients treated with anti-EGFR monoclonal antibodies. Clin Colorectal Cancer 2014;13:37-45 e34.
84. Ruzzo A, Graziano F, Vincenzi B, Canestrari E, Perrone G, Galluccio N, Catalano V, Loupakis F, Rabitti C, Santini D, Tonini G, Fiorentini G, Rossi D, Falcone A, Magnani M: High let-7a microRNA levels in KRAS-mutated colorectal carcinomas may rescue anti-EGFR therapy effects in patients with chemotherapy-refractory metastatic disease. Oncologist 2012;17:823-829.
85. Sha D, Lee AM, Shi Q, Alberts SR, Sargent DJ, Sinicrope FA, Diasio RB: Association study of the let-7 miRNA-complementary site variant in the 3' untranslated region of the KRAS gene in stage III colon cancer (NCCTG N0147 Clinical Trial). Clin Cancer Res 2014;20:3319-3327.
86. Chen X, Ba Y, Ma L, Cai X, Yin Y, Wang K, Guo J, Zhang Y, Chen J, Guo X, Li Q, Li X, Wang W, Zhang Y, Wang J, Jiang X, Xiang Y, Xu C, Zheng P, Zhang J, Li R, Zhang H, Shang X, Gong T, Ning G, Wang J, Zen K, Zhang J, Zhang CY: Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res 2008;18:997-1006.
87. Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL, Peterson A, Noteboom J, O'Briant KC, Allen A, Lin DW, Urban N, Drescher CW, Knudsen BS, Stirewalt DL, Gentleman R, Vessella RL, Nelson PS, Martin DB, Tewari M: Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A 2008;105:10513-10518.
88. Slaby O, Svoboda M, Michalek J, Vyzula R: MicroRNAs in colorectal cancer: translation of molecular biology into clinical application. Mol Cancer 2009;8:102.
89. Kjersem JB, Ikdahl T, Lingjaerde OC, Guren T, Tveit KM, Kure EH: Plasma microRNAs predicting clinical outcome in metastatic colorectal cancer patients receiving first-line oxaliplatin-based treatment. Mol Oncol 2014;8:59-67.
90. Chen Q, Xia H-W, Ge X-J, Zhang Y-C, Tang Q-L, Bi F: Serum miR-19a Predicts Resistance to FOLFOX Chemotherapy in Advanced Colorectal Cancer Cases. Asian Pac J Cancer Prev 2013;14:7421-7426.
91. Zhang J, Zhang K, Bi M, Jiao X, Zhang D, Dong Q: Circulating microRNA expressions in colorectal cancer as predictors of response to chemotherapy. Anticancer Drugs 2014;25:346-352.
92. Chen J, Wang W, Zhang Y, Chen Y, Hu T: Predicting distant metastasis and chemoresistance using plasma miRNAs. Med Oncol 2014;31:799.
93. Schou JV, Rossi S, Jensen BV, Nielsen DL, Pfeiffer P, Hogdall E, Yilmaz M, Tejpar S, Delorenzi M, Kruhoffer M, Johansen JS: miR-345 in metastatic colorectal cancer: a non-invasive biomarker for clinical outcome in non-KRAS mutant patients treated with 3rd line cetuximab and irinotecan. PLoS One 2014;9:e99886.
94. Hayes J, Peruzzi PP, Lawler S: MicroRNAs in cancer: biomarkers, functions and therapy. Trends Mol Med 2014;20:460-469.
95. Garzon R, Marcucci G, Croce CM: Targeting microRNAs in cancer: rationale, strategies and challenges. Nat Rev Drug Discov 2010;9:775-789.
96. Vester B, Wengel J: LNA (locked nucleic acid): high-affinity targeting of complementary RNA and DNA. Biochemistry 2004;43:13233-13241.
97. Calin GA, Croce CM: MicroRNA signatures in human cancers. Nat Rev Cancer 2006;6:857-866.
98. Nedaeinia R, Sharifi M, Avan A, Kazemi M, Rafiee L, Ghayour-Mobarhan M, Salehi R: Locked nucleic acid anti-miR-21 inhibits cell growth and invasive behaviors of a colorectal adenocarcinoma cell line: LNA-anti-miR as a novel approach. Cancer Gene Ther 2016;23:246-253.
99. Chen X, Guo X, Zhang H, Xiang Y, Chen J, Yin Y, Cai X, Wang K, Wang G, Ba Y, Zhu L, Wang J, Yang R, Zhang Y, Ren Z, Zen K, Zhang J, Zhang CY: Role of miR-143 targeting KRAS in colorectal tumorigenesis. Oncogene 2009;28:1385-1392.
100. Dassow H, Aigner A: MicroRNAs (miRNAs) in colorectal cancer: from aberrant expression towards therapy. Curr Pharm Des 2013;19:1242-1252.
101. Jin D, Fang Y, Li Z, Chen Z, Xiang J: Epithelial-mesenchymal transition-associated microRNAs in colorectal cancer and drug-targeted therapies (Review). Oncol Rep 2015;33:515-525.
102. Bu P, Chen KY, Chen JH, Wang L, Walters J, Shin YJ, Goerger JP, Sun J, Witherspoon M, Rakhilin N, Li J, Yang H, Milsom J, Lee S, Zipfel W, Jin MM, Gumus ZH, Lipkin SM, Shen X: A microRNA miR-34a-regulated bimodal switch targets Notch in colon cancer stem cells. Cell Stem Cell 2013;12:602-615.
103. Ibrahim AF, Weirauch U, Thomas M, Grunweller A, Hartmann RK, Aigner A: MicroRNA replacement therapy for miR-145 and miR-33a is efficacious in a model of colon carcinoma. Cancer Res 2011;71:5214-5224.
104. Jarry J, Schadendorf D, Greenwood C, Spatz A, van Kempen LC: The validity of circulating microRNAs in oncology: five years of challenges and contradictions. Mol Oncol 2014;8:819-829.
105. Li Y, Kowdley KV: Method for microRNA isolation from clinical serum samples. Anal Biochem 2012;431:69-75.
106. Gilsbach R, Kouta M, Bonisch H, Bruss M: Comparison of in vitro and in vivo reference genes for internal standardization of real-time PCR data. Biotechniques 2006;40:173-177.